What is AbCellera Biologics Inc.'s stock-based comp?

AbCellera Biologics Inc. (ABCL) reported stock-based comp of $12.01M in Q1 2026.

How has AbCellera Biologics Inc.'s stock-based comp changed year-over-year?

AbCellera Biologics Inc.'s stock-based comp decreased by 18.8% year-over-year, from $14.79M to $12.01M.

What is the long-term trend for AbCellera Biologics Inc.'s stock-based comp?

Over 4 years (2021 to 2025), AbCellera Biologics Inc.'s stock-based comp has grown at a 16.2% compound annual growth rate (CAGR), from $30.65M to $55.79M.

AbCellera Biologics Inc. ABCL Stock-Based Comp

Stock-Based Comp at other companies

ZymeworksZYME

——

ADMA BiologicsADMA

——

Roivant SciencesROIV

——

RevvityRVTY

——

BioCryst PharmaceuticalsBCRX

——

Other financials

Income statement

See full

Revenue$8.3M+96.3%

Operating income-$57.5M+8.2%

Net income-$43.2M+5.4%

EPS (diluted)-$0.14+6.7%

Balance sheet

See full

Cash & equivalents$102.1M-44.6%

Total debt$140.2M+107%

Total equity$938.1M-8.3%

Total assets$1.3B-2.8%

Cash flow

See full

Operating cash flow-$33.5M-190%

CapEx$3.8M-64.0%

Free cash flow-$37.4M-68.3%

Valuation

See full

Market cap$1.84B+59.2%

Enterprise value$1.88B+100.0%

P/S23.3×-26.8×

Profitability

See full

Operating margin-267.6%-120pp

Net margin-181.7%-77.9pp

FCF margin-238.9%-90.9pp

Returns & leverage

See full

Return on equity-14.7%-0.8pp

Debt / equity0.1×+0.1×

Current ratio14.1×+3.9×

Where this comes from

Reported directly by AbCellera Biologics Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about AbCellera Biologics Inc.'s stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is AbCellera Biologics Inc.'s stock-based comp?: AbCellera Biologics Inc. (ABCL) reported stock-based comp of $12.01M in Q1 2026.
How has AbCellera Biologics Inc.'s stock-based comp changed year-over-year?: AbCellera Biologics Inc.'s stock-based comp decreased by 18.8% year-over-year, from $14.79M to $12.01M.
What is the long-term trend for AbCellera Biologics Inc.'s stock-based comp?: Over 4 years (2021 to 2025), AbCellera Biologics Inc.'s stock-based comp has grown at a 16.2% compound annual growth rate (CAGR), from $30.65M to $55.79M.